Inicio › Enfermedad de obstrucción pulmonar crónica › Alabama
Ensayos clínicos de Enfermedad de obstrucción pulmonar crónica en Alabama
20 estudios sobre Enfermedad de obstrucción pulmonar crónica buscan participantes en Alabama.
Ciudades en Alabama
Texto oficial del estudio (inglés)
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 2
Edades de 40 a 75 · Todos los sexos · Actualizado el 5 nov 2026 · NCT07759245Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
- University of Alabama-Birmingham Hospital - UAB Lung Health Center, Birmingham
Reclutando
Edades de 40 a 80 · Todos los sexos · Actualizado el 5 nov 2026 · NCT07051707Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 4
Edades de 19 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT07135427A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
- GC2501 Study Site 106, Birmingham
ReclutandoFase 3
Edades de 18 a 80 · Todos los sexos · Actualizado el 26 oct 2026 · NCT07555483A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Birmingham
ReclutandoFase 2
Edades de 40 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT07082738Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- University of Alabama at Birmingham- Site Number : 8400003, Birmingham
- Pulmonary Associates - Mobile- Site Number : 8400151, Mobile
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 23 oct 2026 · NCT07190222A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- University of Alabama at Birmingham Lung Health Center, Birmingham
- SEC Clinical Research, Dothan
- Pulmonary Associates of Mobile, P.C., Mobile
ReclutandoFase 2/3
Edades de 35 a 80 · Todos los sexos · Actualizado el 22 oct 2026 · NCT07363694A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
- University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, Birmingham
ReclutandoFase 4
Edades de 40 a 85 · Todos los sexos · Actualizado el 20 oct 2026 · NCT07053423Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
- University of Alabama at Birmingham, Birmingham
Reclutando
Edades de 40 a 84 · Todos los sexos · Actualizado el 19 oct 2026 · NCT06891755A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Birmingham
- Research Site, Cullman
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 9 oct 2026 · NCT06878261Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Sheffield
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 5 oct 2026 · NCT06961214A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Cullman
- Research Site, Mobile
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 2 oct 2026 · NCT06283966Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- University of Alabama, Birmingham
ReclutandoFase 2
Edades de 40 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Foley
- Research Site, Mobile
- Research Site, Sheffield
ReclutandoFase 3
Edades de 40 a 80 · Todos los sexos · Actualizado el 3 sept 2026 · NCT06883305Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities
- Cooper Green Mercy Hospital, Birmingham
ReclutandoEstudio observacional
Edades de 50 a 99 · Todos los sexos · Actualizado el 6 ago 2026 · NCT07748858Multi-Center Clean Air Randomized Controlled Trial in COPD
- University of Alabama, Lung Health Center, Birmingham
ReclutandoFase 3
Edades de 40 en adelante · Todos los sexos · Actualizado el 31 jul 2026 · NCT06376994Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
- The University of Alabama at Birmingham, Birmingham
Reclutando
Edades de 22 en adelante · Todos los sexos · Actualizado el 23 jun 2026 · NCT07222410SPIROMICS Study of Early COPD Progression (SOURCE)
- University of Alabama at Birmingham, Birmingham
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 30 a 55 · Todos los sexos · Actualizado el 3 jun 2026 · NCT05033990PiMZ Longitudinal Cohort (PiMZ Logic)
- University of Alabama at Birmingham, Birmingham
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 ene 2026 · NCT06505603myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- UAB School of Medicine/Lung Health Center, Birmingham
Reclutando
Edades de 30 en adelante · Todos los sexos · Actualizado el 6 feb 2025 · NCT05204888De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.